Enlivex Therapeutics (ENLV) Set to Release Earnings on Friday

Enlivex Therapeutics (NASDAQ:ENLV) will likely be posting its results on Friday, November 13th. Analysts expect the company to announce earnings of ($4.48) per share for the quarter.

Enlivex Therapeutics Stock Down 12.4%

Shares of NASDAQ:ENLV opened at $1.20 on Wednesday. Enlivex Therapeutics has a fifty-two week low of $1.20 and a fifty-two week high of $434.40. The business has a 50-day moving average of $7.51 and a two-hundred day moving average of $131.49.

Analyst Ratings Changes

ENLV has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. Zacks Research lowered Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, October 2nd. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $4,800.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.